PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 9916475

[A computed tomography-based study of features developmental patterns: Mycobacterium avium complex without predisposing conditions].

H Kawamoto
View original source ↗Export metadata ↓

Abstract

The aim of this study was to determine the computed tomographic (CT) features and developmental patterns of Mycobacterium avium complex disease (MAC disease). The author examined chest CT films from 36 cases of MAC without predisposing conditions, 8 early-stage cases, and 6 long-term follow-up cases. Prominent CT features included centrilobular abnormalities (in the lower part of the right upper lobe, middle lobe, and lingula predominance), airspace consolidation, and bronchiectasis in the middle lobe and lingula. Patterns of development typically began with centrilobular abnormalities in the lower part of the right upper lobe, middle lobe, or lingula. These centrilobular abnormalities tended to fuse, leading to airspace consolidation in the middle lobe and lingula. Bronchial wall thickening was followed by bronchiectasis in the middle lobe and lingula. These CT-image features and patterns (centrilobular abnormalities, airspace consolidation, and bronchiectasis) were thought to be manifestations of sequential phases of MAC disease development.

Explore related subjects

Disease ProgressionFemaleHumansLungMaleMiddle AgedMycobacterium avium-intracellulare InfectionTomography, X-Ray ComputedTuberculosis, PulmonaryJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H Kawamoto. 1998. [A computed tomography-based study of features developmental patterns: Mycobacterium avium complex without predisposing conditions].. https://pubmed.ncbi.nlm.nih.gov/9916475/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2004

Upregulation of the androgen receptor during prostate cancer progression.

The androgen receptor is one of the central factors in mediating prostate cancer progression and is an important target for treatment. Several possible mechanisms have been put forth as to how it promotes this process. In the January 2004 issue of Nature Medicine, Chen et al. report that the androgen receptor is consistently upregulated as hormone sensitive prostate cancer changes to a hormone refractory state. They also show that this change is intricately involved during the development of resistance to androgen ablation therapy.

Disease Progression↗
PubMed2004

Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence.

Despite earlier detection and recent advances in surgery and radiation, prostate cancer is second only to lung cancer in male cancer deaths in the United States. Hormone therapy in the form of medical or surgical castration remains the mainstay of systemic treatment in prostate cancer. Over the last 15 years with the clinical use of prostate specific antigen (PSA), there has been a shift to using hormone therapy earlier in the disease course and for longer duration. Despite initial favorable response to hormone therapy, over a period of time these tumors will develop androgen-independence that results in death. The androgen receptor (AR) is central to the initiation and growth of prostate cancer and to its response to hormone therapy. Analyses have shown that AR continues to be expressed in androgen-independent tumors and AR signaling remains intact as demonstrated by the expression of the AR regulated gene, PSA. Androgen-independent prostate cancers have demonstrated a variety of AR alterations that are either not found in hormone naïve tumors or found at lower frequency. These changes include AR amplification, AR point mutation, and changes in expression of AR co-regulatory proteins. These AR changes result in a "super AR" that can respond to lower concentrations of androgens or to a wider variety of agonistic ligands. There is also mounting evidence that AR can be activated in a ligand independent fashion by compounds such as growth factors or cytokines working independently or in combination. These growth factors working through receptor tyrosine kinase pathways may promote AR activation and growth in low androgen environments. The clinical significance of these AR alterations in the development and progression of androgen-independent prostate cancer remains to be determined. Understanding the changes in AR signaling in the evolution of androgen-independent prostate cancer will be key to the development of more effective hormone therapy.

Disease Progression↗